236 related articles for article (PubMed ID: 17669232)
1. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data.
Yu AP; Wu EQ; Birnbaum HG; Emani S; Fay M; Pohl G; Wintle M; Yang E; Oglesby A
Curr Med Res Opin; 2007 Sep; 23(9):2157-69. PubMed ID: 17669232
[TBL] [Abstract][Full Text] [Related]
2. Healthcare costs associated with change in body mass index in patients with type 2 diabetes mellitus in Spain: the ECOBIM study.
Dilla T; Valladares A; Nicolay C; Salvador J; Reviriego J; Costi M
Appl Health Econ Health Policy; 2012 Nov; 10(6):417-30. PubMed ID: 23013427
[TBL] [Abstract][Full Text] [Related]
3. Association Between Weight Change, Clinical Outcomes, and Health Care Costs in Patients with Type 2 Diabetes.
Mukherjee J; Sternhufvud C; Smith N; Bell K; Stott-Miller M; McMorrow D; Johnston S
J Manag Care Spec Pharm; 2016 May; 22(5):449-66. PubMed ID: 27123909
[TBL] [Abstract][Full Text] [Related]
4. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
[TBL] [Abstract][Full Text] [Related]
5. Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic Control.
Karkare S; Fridman M; Dang-Tan T; Lu J; Smolarz BG; DeKoven M; Iyer NN
J Manag Care Spec Pharm; 2019 Jun; 25(6):658-668. PubMed ID: 30730232
[TBL] [Abstract][Full Text] [Related]
6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
7. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study.
Balkrishnan R; Rajagopalan R; Camacho FT; Huston SA; Murray FT; Anderson RT
Clin Ther; 2003 Nov; 25(11):2958-71. PubMed ID: 14693318
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data.
McAdam-Marx C; Mukherjee J; Bellows BK; Unni S; Ye X; Iloeje U; Brixner DI
Diabetes Res Clin Pract; 2014 Mar; 103(3):402-11. PubMed ID: 24503045
[TBL] [Abstract][Full Text] [Related]
9. Economic value of nonsurgical weight loss in adults with obesity.
Ding Y; Fan X; Blanchette CM; Smolarz BG; Weng W; Ramasamy A
J Manag Care Spec Pharm; 2021 Jan; 27(1):37-50. PubMed ID: 33164723
[No Abstract] [Full Text] [Related]
10. Effect of Diabetes Treatment-Related Attributes on Costs to Type 2 Diabetes Patients in a Real-World Population.
Meng J; Casciano R; Lee YC; Stern L; Gultyaev D; Tong L; Kitio-Dschassi B
J Manag Care Spec Pharm; 2017 Apr; 23(4):446-452. PubMed ID: 28345434
[TBL] [Abstract][Full Text] [Related]
11. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study.
Mody R; Huang Q; Yu M; Patel H; Zhang X; Wang L; Grabner M
BMJ Open Diabetes Res Care; 2019; 7(1):e000884. PubMed ID: 31875137
[TBL] [Abstract][Full Text] [Related]
13. Cost and clinical impact of a nonmedical DPP-4 inhibitor switch in patients with diabetes.
Kheloussi S; Johns A; Parente V; McLay W; Gionfriddo MR
J Manag Care Spec Pharm; 2021 Jul; 27(7):846-854. PubMed ID: 34185559
[No Abstract] [Full Text] [Related]
14. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus.
Maetzel A; Ruof J; Covington M; Wolf A
Pharmacoeconomics; 2003; 21(7):501-12. PubMed ID: 12696990
[TBL] [Abstract][Full Text] [Related]
15. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes.
Shetty S; Secnik K; Oglesby AK
J Manag Care Pharm; 2005 Sep; 11(7):559-64. PubMed ID: 16137213
[TBL] [Abstract][Full Text] [Related]
16. Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.
Lage MJ; Fabunmi R; Boye KS; Misurski DA
Adv Ther; 2009 Feb; 26(2):217-29. PubMed ID: 19219409
[TBL] [Abstract][Full Text] [Related]
17. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
Chakravarty A; Rastogi M; Dhankhar P; Bell KF
J Med Econ; 2018 May; 21(5):497-509. PubMed ID: 29376760
[TBL] [Abstract][Full Text] [Related]
18. Economic impact of moderate weight loss in patients with Type 2 diabetes: the Fremantle Diabetes Study.
Davis WA; Bruce DG; Davis TM
Diabet Med; 2011 Sep; 28(9):1131-5. PubMed ID: 21843308
[TBL] [Abstract][Full Text] [Related]
19. Economic implications of weight change in patients with type 2 diabetes mellitus.
Bell K; Parasuraman S; Shah M; Raju A; Graham J; Lamerato L; D'Souza A
Am J Manag Care; 2014 Aug; 20(8):e320-9. PubMed ID: 25295795
[TBL] [Abstract][Full Text] [Related]
20. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
